Pharmacokinetics and Pharmacodynamics Practice Questions

Q: What does the plasma concentration versus time graph indicate?

Bioavailability. ***Bioavailability*** - The **plasma concentration versus time graph** is primarily used to calculate bioavailability by comparing the **area under the curve (AUC)** between different routes of administration (oral vs IV). - **Bioavailability (F)** is determined using the formula: F = AUC_oral / AUC_IV × Dose_IV / Dose_oral, making this graph essential for **bioequivalence studies**. *Half-life* - **Half-life** is derived from the **elimination phase slope** of the plasma concentration curve, not the overall graph comparison. - It represents the time required for plasma concentration to decrease by **50%** and is calculated from a single curve's declining phase. *Clearance* - **Clearance** is calculated using the formula **Dose/AUC** and represents the volume of plasma cleared per unit time. - While the graph provides AUC data needed for clearance calculation, the graph itself doesn't directly indicate clearance. *Elimination* - **Elimination rate constant** is determined from the **slope of the terminal elimination phase** of a single concentration-time curve. - The graph comparison between routes doesn't directly measure elimination kinetics but rather **absorption and bioavailability differences**.

Q: Phase II drug metabolism reactions include all of the following EXCEPT:

Reduction. Drug metabolism (biotransformation) typically occurs in two phases to make lipophilic drugs more polar for excretion. **Phase I Reactions (Functionalization):** These reactions introduce or expose a functional group (–OH, –NH2, –SH). They include **Oxidation** (most common, via CYP450), **Reduction**, and **Hydrolysis**. * **Reduction** is a Phase I reaction; therefore, it is the correct answer to the "EXCEPT" question. Examples of drugs undergoing reduction include Chloramphenicol and Halothane. **Phase II Reactions (Conjugation):** These involve the attachment of an endogenous group to the drug to form a highly polar, inactive metabolite. * **Acetylation (Option A):** A Phase II reaction mediated by N-acetyltransferase (NAT). Important for drugs like Isoniazid, Hydralazine, and Procainamide. * **Glycine Conjugation (Option B):** A Phase II reaction. A classic example is the conversion of Salicylic acid to Salicyluric acid. * **Methylation (Option C):** A Phase II reaction mediated by methyltransferases. Examples include the metabolism of Epinephrine and Dopamine. **High-Yield Clinical Pearls for NEET-PG:** * **Mnemonic for Phase I:** **HOR** (Hydrolysis, Oxidation, Reduction). * **Mnemonic for Phase II:** **G**ASP **M**e (Glucuronidation, Acetylation, Sulfation, Phosphorylation, Methylation). * **Glucuronidation** is the most common Phase II reaction. * **Microsomal vs. Non-microsomal:** Most Phase I enzymes are microsomal (located in the SER), while most Phase II enzymes are non-microsomal (cytosolic), with the notable exception of **Glucuronosyltransferase**, which is microsomal. * **Gray Baby Syndrome:** Occurs in neonates due to deficient Glucuronidation of Chloramphenicol.

Q: A new antifungal medication has a half-life of 6 hours. If a continuous intravenous infusion of this drug were started, how long would it take to reach 75% of steady state?

12 hours. ### Explanation The time required to reach a steady-state concentration ($C_{ss}$) during a continuous intravenous infusion is determined solely by the drug's **half-life ($t_{1/2}$)** [1]. It is independent of the dose or the rate of infusion. **The Rule of Half-Lives:** The accumulation of a drug toward steady state follows first-order kinetics [2]: * 1 Half-life $\rightarrow$ 50% of $C_{ss}$ * **2 Half-lives $\rightarrow$ 75% of $C_{ss}$** * 3 Half-lives $\rightarrow$ 87.5% of $C_{ss}$ * 4 to 5 Half-lives $\rightarrow$ >90% (Clinically considered steady state) In this question, the half-life is **6 hours**. To reach 75% of the steady state, the drug must pass through 2 half-lives. Calculation: $2 \times 6 \text{ hours} = \mathbf{12 \text{ hours}}$. --- ### Analysis of Options: * **A (3 hours):** This represents 0.5 half-lives; the drug concentration would be significantly below the therapeutic steady state. * **B (6 hours):** This is 1 half-life, at which point the drug reaches only 50% of its steady-state concentration. * **C (9 hours):** This is 1.5 half-lives, resulting in approximately 62.5% of $C_{ss}$. * **D (12 hours):** **Correct.** As calculated, 2 half-lives are required to reach 75% of $C_{ss}$. --- ### NEET-PG High-Yield Pearls: 1. **Steady State Principle:** It takes approximately **4–5 half-lives** to reach clinical steady state ($>93\%$) and the same amount of time to completely eliminate a drug from the body after stopping the infusion [1]. 2. **Loading Dose:** If a rapid therapeutic effect is needed (e.g., in emergencies), a **Loading Dose** is given to bypass the delay caused by the half-life [3]. It does not change the time to reach steady state but achieves the target concentration immediately. 3. **Formula:** $C_{ss} = \text{Infusion Rate} / \text{Clearance}$. Note that half-life is not in the formula for the *level* of $C_{ss}$, only the *time* to reach it [2].

Q: Loading dose is given for which of the following drugs?

Chloroquine. **Explanation:** The correct answer is **Chloroquine**. **1. Why Chloroquine is correct:** The primary pharmacological reason for giving a loading dose is to rapidly achieve the **steady-state plasma concentration ($C_{ss}$)** for drugs with a **large volume of distribution ($V_d$)** or a **long half-life ($t_{1/2}$)**. Chloroquine has an exceptionally high $V_d$ (approx. 13,000 L) because it extensively binds to tissues (melanin in eyes, liver, and muscles). Without a loading dose, it would take weeks to reach therapeutic levels. In clinical practice (e.g., treating malaria), a loading dose of 600 mg base is given initially, followed by 300 mg to ensure immediate therapeutic efficacy against the parasite. **2. Why other options are incorrect:** * **Diazepam:** It is a lipid-soluble benzodiazepine with a relatively rapid onset. While it has a long half-life due to active metabolites, it does not require a loading dose for its standard sedative or anxiolytic effects. * **Propranolol:** It undergoes significant first-pass metabolism. Dosage is usually titrated based on heart rate and clinical response rather than a calculated loading dose. * **Aspirin:** Used primarily for its antiplatelet (low dose) or analgesic/anti-inflammatory effects. It has a short half-life and reaches effective concentrations quickly without a loading dose. **3. High-Yield Clinical Pearls for NEET-PG:** * **Formula:** $\text{Loading Dose} = \frac{V_d \times \text{Target } C_{p}}{\text{Bioavailability (F)}}$. * **Key Concept:** Loading dose depends on **Volume of Distribution**, whereas Maintenance Dose depends on **Clearance**. * **Other drugs requiring loading doses:** Amiodarone (very high $V_d$), Digoxin, Phenytoin, and Teicoplanin. * **Caution:** Loading doses carry a higher risk of toxicity; for example, rapid IV injection of a loading dose of Phenytoin or Aminophylline can cause cardiac arrhythmias.

Q: Urinary alkalization increases urine elimination of all the following drugs, except:

Amphetamine. ### Explanation The core principle behind this question is **Ion Trapping**, which is based on the **Henderson-Hasselbalch equation**. This concept dictates that a drug in its ionized (charged) form cannot easily cross lipid membranes and is therefore trapped in the renal tubules, leading to increased excretion. **1. Why Amphetamine is the Correct Answer:** Amphetamine is a **weak base**. According to the principle of ion trapping, weak bases are ionized in **acidic environments**. Therefore, to increase the renal elimination of Amphetamine, the urine must be **acidified** (e.g., using Ammonium Chloride). Alkalizing the urine would make Amphetamine non-ionized, promoting its reabsorption back into the bloodstream. **2. Why the Other Options are Incorrect:** * **Salicylate (A):** Aspirin is a weak acid. Alkalizing the urine (using Sodium Bicarbonate) converts it into its ionized form, preventing reabsorption and promoting excretion. This is a standard treatment for salicylate poisoning. * **Methotrexate (B):** This is a weak acid. Urinary alkalization is clinically used during high-dose methotrexate therapy to increase its solubility and excretion, preventing crystal-induced nephrotoxicity. * **Phenobarbital (C):** A long-acting barbiturate and a weak acid. Alkalization of urine is a mainstay in managing its toxicity to enhance renal clearance. **High-Yield Clinical Pearls for NEET-PG:** * **Rule of Thumb:** "Like dissolves in like, but opposites ionize." * **Acidic drugs** (Salicylates, Barbiturates, MTX) $\rightarrow$ Excreted in **Alkaline urine**. * **Basic drugs** (Amphetamines, Morphine, Quinine) $\rightarrow$ Excreted in **Acidic urine**. * **Agent for Alkalization:** IV Sodium Bicarbonate ($NaHCO_3$). * **Agent for Acidification:** Ammonium Chloride ($NH_4Cl$) or Vitamin C (though rarely used clinically due to risk of metabolic acidosis).

Q: Chloroquine is given in a high loading dose primarily because of which pharmacokinetic property?

High volume of distribution. **Explanation:** **1. Why High Volume of Distribution (Vd) is correct:** Chloroquine is a highly lipophilic drug that exhibits extensive tissue binding, particularly in the liver, spleen, kidneys, and melanin-containing tissues (like the retina). This results in an exceptionally high **Volume of Distribution (Vd)**—often exceeding 10,000 L. In pharmacokinetics, the **Loading Dose (LD)** is calculated using the formula: $LD = Vd \times Target\ Plasma\ Concentration$. Since Chloroquine sequesters heavily into tissues, a large initial dose is required to saturate these tissue binding sites and rapidly achieve the therapeutic plasma concentration necessary to exert its antimalarial effect. Without a loading dose, it would take several weeks to reach a steady state. **2. Why other options are incorrect:** * **B. Poor gastrointestinal absorption:** Chloroquine is actually absorbed very rapidly and almost completely (>80%) from the GI tract. Poor absorption would necessitate parenteral administration, not a specific loading dose strategy. * **C. High first-pass metabolism:** Chloroquine does not undergo significant first-pass metabolism; its bioavailability is high. Drugs with high first-pass metabolism (like Nitroglycerin) are usually given via non-oral routes. **3. NEET-PG High-Yield Pearls:** * **Amiodarone and Digoxin** are other classic examples of drugs requiring loading doses due to high Vd and extensive tissue sequestration. * **Chloroquine Toxicity:** Due to its affinity for melanin, long-term use can lead to **"Bull’s eye maculopathy"** (retinopathy). * **Half-life:** Because of its high Vd, Chloroquine has a very long terminal half-life (30–60 days).

Q: Which of the following drugs has high plasma protein binding to serum albumin?

Warfarin. ### Explanation **1. Why Warfarin is Correct:** The binding of drugs to plasma proteins is primarily determined by their chemical nature. **Acidic drugs** [2] (like Warfarin [1], NSAIDs, Sulfonamides, and Phenytoin) bind predominantly to **Serum Albumin**. Warfarin is highly protein-bound (>99%) [1]. This is clinically significant because only the "free" fraction of the drug is pharmacologically active [3]. Drugs with high albumin binding are prone to displacement interactions; for example, if another drug displaces Warfarin from albumin, it can lead to a sudden increase in free Warfarin levels, resulting in hemorrhage. **2. Why Other Options are Incorrect:** * **Lignocaine & Quinidine:** These are **basic drugs**. Basic drugs do not primarily bind to albumin; instead, they bind to **$\alpha_1$-acid glycoprotein (AAG)** [4]. * **All of the above:** This is incorrect because the question specifically asks for binding to *serum albumin*, which is selective for acidic drugs. **3. High-Yield NEET-PG Pearls:** * **Albumin vs. AAG:** Remember the mnemonic: **"A for A"** (Acidic drugs bind to Albumin) and **"B for B"** (Basic drugs bind to $\alpha_1$-acid glycoprotein/Beta-globulin). * **Clinical Impact:** High protein binding usually results in a **low Volume of Distribution ($V_d$)** because the drug is sequestered within the vascular compartment. * **Disease States:** In **Hypoalbuminemia** (e.g., Nephrotic syndrome, Cirrhosis), the dose of highly protein-bound drugs like Warfarin or Phenytoin must be reduced to avoid toxicity [2]. * **AAG Levels:** $\alpha_1$-acid glycoprotein is an acute-phase reactant; its levels increase during inflammation, surgery, or trauma, potentially decreasing the free fraction of basic drugs like Lignocaine [4].

Q: What is characteristic of an agonist?

Affinity with intrinsic activity of 1. ### Explanation In pharmacology, the interaction between a drug and its receptor is defined by two key parameters: **Affinity** (the ability of a drug to bind to a receptor) and **Intrinsic Activity/Efficacy** (the ability of a drug to activate the receptor and produce a biological response). **Why Option A is Correct:** An **Agonist** is a drug that possesses both affinity and maximal intrinsic activity. By convention, the intrinsic activity (IA) of a full agonist is **1**. This means that upon binding, the drug induces a conformational change in the receptor that triggers the maximum possible biological effect. **Analysis of Incorrect Options:** * **Option B (IA = 0):** This describes an **Antagonist**. An antagonist has affinity (it binds to the receptor) but zero intrinsic activity. It produces no response of its own but prevents an agonist from binding. * **Option C (IA = -1):** This describes an **Inverse Agonist**. These drugs bind to receptors that have "constitutive activity" (spontaneous activity in the absence of a ligand) and suppress this baseline activity, producing an effect opposite to that of an agonist. * **Partial Agonists (Note):** These have affinity but an intrinsic activity between **0 and 1**. **NEET-PG High-Yield Pearls:** 1. **Intrinsic Activity Scale:** * Full Agonist: 1 * Partial Agonist: >0 to <1 * Antagonist: 0 * Inverse Agonist: -1 2. **Clinical Correlation:** A partial agonist (e.g., **Pindolol** or **Buprenorphine**) can act as an antagonist in the presence of a full agonist by displacing it from receptors, a phenomenon known as "dual action." 3. **Potency vs. Efficacy:** Efficacy (Intrinsic Activity) is clinically more important than potency. A drug with higher efficacy is more effective for severe conditions, regardless of the dose required.

Question 1

What does the plasma concentration versus time graph indicate?

Accepted Answer

Bioavailability

Answer

Half-life

Answer

Clearance

Answer

Elimination

Question 2

Phase II drug metabolism reactions include all of the following EXCEPT:

Accepted Answer

Reduction

Answer

Acetylation

Answer

Glycine conjugation

Answer

Methylation

Question 3

A new antifungal medication has a half-life of 6 hours. If a continuous intravenous infusion of this drug were started, how long would it take to reach 75% of steady state?

Accepted Answer

12 hours

Answer

3 hours

Answer

6 hours

Answer

9 hours

Question 4

Loading dose is given for which of the following drugs?

Accepted Answer

Chloroquine

Answer

Diazepam

Answer

Propranolol

Answer

Aspirin

Question 5

Urinary alkalization increases urine elimination of all the following drugs, except:

Accepted Answer

Amphetamine

Answer

Salicylate

Answer

Methotrexate

Answer

Phenobarbital

Question 6

Chloroquine is given in a high loading dose primarily because of which pharmacokinetic property?

Accepted Answer

High volume of distribution

Answer

Poor gastrointestinal absorption

Answer

High first-pass metabolism

Answer

All of the above

Question 7

Which of the following statements regarding zero-order kinetics is true?

Accepted Answer

Clearance decreases with an increase in plasma concentration.

Answer

Half-life is constant.

Answer

The rate of elimination is dependent on plasma drug concentration.

Answer

It applies to the majority of drugs.

Question 8

Which of the following drugs has high plasma protein binding to serum albumin?

Accepted Answer

Warfarin

Answer

Lignocaine

Answer

Quinidine

Answer

All of the above

Question 9

What is characteristic of an agonist?

Accepted Answer

Affinity with intrinsic activity of 1

Answer

Affinity with intrinsic activity of 0

Answer

Affinity with intrinsic activity of -1

Answer

None of the above

Question 10

What is the typical outcome for a drug after undergoing Phase II biotransformation reactions?

Accepted Answer

Increased water solubility

Answer

Less bioreactive

Answer

Increased bioavailability

Answer

Increased lipid solubility

Pharmacokinetics and Pharmacodynamics — MCQs

Pharmacokinetics and Pharmacodynamics — MCQs

On this page

Practice by Chapter

Want unlimited practice?